PRKCSH and lung carcinoma: To further investigate whether PRKCSH is involved in acquired resistance to TNFSF-mediated cytotoxicity, we first established acquired TRAIL-resistant cells, denoted H292R (lung cancer cells) and HepG2R (hepatoma cells) from TRAIL-sensitive H292S and HepG2S cells, respectively, by long-term culture under TRAIL treatment.